ArticleBMC medical genomics2025
Overexpression of cancer testis antigens in gastric cancer and their correlations with the patients' clinicopathological characteristics.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-testis antigens are typically expressed in malignant cells, germ-line cells, and the placenta. Given their potential as targets for cancer immunotherapy, it is essential to profile their expression. This study examines the clinical significance of MAGE-A4, LAGE-1, and NY-ESO expression levels in gastric cancer compared to normal tissues.
methodsRNA was isolated from fresh gastric specimens of 76 patients diagnosed with GC before any therapeutic intervention. The Real-Time PCR evaluated the MAGE-A4, LAGE-1, and NY-ESO relative mRNA levels. Gene expression was normalized to GAPDH using the ΔΔCt method. Fold changes > 2 with p < 0.05 were considered statistically significant.
resultsThe results indicated that the elevated mRNA expression levels of MAGE-A4, LAGE-1, and NY-ESO were observed in 21.05%, 22.38%, and 26.32% of the cases, respectively. Furthermore, a substantial upregulation of NY-ESO was noted in non-cardia tumors with T1/2 depth of invasion (p = 0.021). This marked increase in NY-ESO expression was also observed in primary-stage tumors situated in non-cardia regions (p = 0.026). MAGE-A4 expression tended to be higher in lymph node–negative tumors, while NY-ESO expression was associated with overall survival, and LAGE-1 showed variable expression.
conclusionOur research demonstrates that MAGE-A4, LAGE-1, and NY-ESO expression are often upregulated in patients with GC. This overexpression in GC tumors is significantly associated with poor prognosis. Therefore, these may serve as a significant prognostic indicator for gastric cancer, and the cancer-testis antigens could represent a potential therapeutic target for a gastric cancer vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.